211P - A cost-utility analysis of administration schedules of G-CSF for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer: Economic evaluation alongside the REaCT-G trial
| Autor: | Basulaiman, B., Awan, A.A., Hilton, J., Fergusson, D., Stober, C., Vandermeer, L., Saunders, D., Clemons, M., Thavorn, K. |
|---|---|
| Zdroj: | In Annals of Oncology May 2019 30 Supplement 3:iii68-iii68 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|